MTAP-deleted solid tumors
Clinical research is centered on locally advanced and metastatic solid tumors with MTAP deletion, including a broad range of advanced malignancies.
- Metastatic MTAP-deleted solid tumors
- Advanced solid tumor oncology
- Anti-neoplastic activity
The sponsor’s oncology portfolio includes tumor types with high unmet need in advanced disease settings.
Thoracic oncology
Research activity includes non-small cell lung cancer and mesothelioma with MTAP deletion, reflecting interest in aggressive thoracic cancers.
- Squamous NSCLC
- Nonsquamous NSCLC
- Mesothelioma
These studies focus on advanced thoracic malignancies with limited targeted treatment options.
Gastrointestinal and pancreatic cancers
The clinical portfolio also covers pancreatic ductal adenocarcinoma and adenosquamous carcinoma with predominantly adenocarcinoma histology.
- Pancreatic ductal adenocarcinoma
- Adenosquamous carcinoma
- Advanced gastrointestinal oncology
Interest extends to difficult-to-treat pancreatic malignancies within the broader MTAP-deleted population.
Soft tissue and rare solid tumors
Trials include sarcoma and other advanced solid tumors, indicating attention to rarer oncologic subtypes alongside more common cancers.
- Sarcoma
- Other MTAP-deleted solid tumors
- Advanced rare tumor oncology
This area captures additional tumor groups eligible for MTAP-deletion–directed research.
Neuro-oncology
Research also includes relapsed or refractory glioblastoma multiforme and grade 4 astrocytoma with MTAP deletion.
- Glioblastoma multiforme
- Grade 4 astrocytoma
- Recurrent high-grade glioma
These studies address aggressive central nervous system tumors with substantial therapeutic need.
